LMND heads into its Q1 2026 earnings release with short sellers notably reducing pressure — yet a 14.5% short interest figure still looms large over the name.
The borrow market tells a story of easing conviction among bears. Short interest has fallen roughly 6% over the past month and dropped again in the final week before the print to 14.5% of free float — down from above 15% through most of April. The cost to borrow remains negligible at 0.44%, meaning shorts face virtually no carrying cost to hold positions. Borrow availability is wide, reflecting a lending pool that is far from stressed. That combination — high headline short interest but falling position counts and easy borrow — points less to a squeeze setup and more to gradual capitulation among short sellers. The ORTEX short score of 60.9 places this firmly in elevated-but-easing territory, ranking in just the 7th percentile for short score across the universe. Options positioning reinforces the tonal shift: the put/call ratio is running below its 20-day average at 0.63, near a one-year low, suggesting options traders are leaning bullish into the release rather than hedging downside.
The analyst debate reflects the fundamental disagreement at the heart of Lemonade's story. Morgan Stanley's upgrade to Overweight in mid-March — with a $85 target — was the most significant recent move, coming at a bellwether firm and representing a genuine directional change on the stock. Bulls point to the company's AI-driven claims efficiency, improving loss adjustment expense ratios, and the prospect of operating leverage as premiums scale toward $2 billion and beyond. Consensus estimates put Q1 revenue near $252 million, still loss-making at roughly -$0.57 EPS, but with positive operating cash flow as a potential bright spot. Keefe, Bruyette & Woods remains the vocal dissenter, holding an Underperform rating with a $44 target — more than 30% below where the stock trades at $65.77 — citing the gross loss ratio, a DTC channel that has historically struggled in insurance, and the challenge of valuing a company that cannot yet be measured on earnings. The mean analyst price target of $65.11 leaves almost no upside from current levels on a consensus basis, masking the wide dispersion between a $44 bear case and targets above $90 from Cantor Fitzgerald and Truist.
The last earnings release in February delivered a sharp -12.8% one-day move followed by a further -16.1% over five days, resetting the stock materially lower. That print has not been forgotten — the 8.4% recovery over the past month brings LMND back near the consensus mean, meaning the stock is priced for neither a blowout nor a disaster. T. Rowe Price added nearly a million shares in the most recent quarter, making it one of the more actively accumulating institutions in the register. BlackRock also added 486,000 shares. Insider activity has run net negative over the past 90 days: CEO Daniel Schreiber sold roughly $12.9 million worth of stock in January, though the last recorded transaction before the print was a director buy of approximately $485,000 in early March — a modest signal pointing the other way.
The Q1 print will test whether Lemonade's efficiency narrative — specifically its AI-underwriting edge and the trajectory of the gross loss ratio — is translating into durable financial improvement, or whether the February selloff reflected a harder truth about the path to profitability.
See the live data behind this article on ORTEX.
Open LMND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
